Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Combining GLP-1 drugs with structured exercise and nutrition support leads to mostly fat loss. A small retrospective study found that 87.6% of weight lost by participants on semaglutide or tirzepatide came from fat, with no statistically significant loss of lean muscle mass. The findings suggest that supervised lifestyle programs could help preserve muscle during obesity treatment.
One common concern with incretin-based obesity drugs like semaglutide and tirzepatide is that they can cause patients to lose not just fat, but also valuable lean muscle mass. A new small retrospective study suggests that pairing these medications with structured exercise and nutritional support may help protect muscle while still driving meaningful fat loss.
Researchers analyzed DEXA scan data from 11 adults enrolled in a commercial weight management program. Participants took either semaglutide or tirzepatide alongside a supervised regimen of aerobic and strength training exercise (150–300 min/week of moderate activity plus at least two strength sessions) and personalized dietary guidance. The median follow-up was 277 days.
By the Numbers:
Why it matters: While the study is small and lacks a control group, the results are encouraging for clinicians managing patients on incretin-based therapies. Preserving lean mass is critical for long-term metabolic health and physical function, and this study adds to the case for integrating structured lifestyle support into obesity drug programs.
